Immedica Pharma AB

Immedica is a Swedish pharmaceutical company headquartered in Stockholm, dedicated to the commercialization of medicines for rare and specialty diseases. Founded in 2018, it has over 140 employees and revenues above SEK 1 billion. It covers rare metabolic, neurological, hematology and oncology conditions. Commercial presence in 50+ countries including Europe, Middle East and North America. Acquired by KKR and Impilo in 2024.